Announcements

Just launched — our new member blog!

Registration for the virtual Fall 2020 Group Meeting opens in mid-Sept.

View the latest Fall 2020 Group Meeting schedule

View the ECOG-ACRIN Health Equity Inaugural Meeting webcast 

In case you missed it, the Q2 TMIST Study Updates Newsletter

Read our Advocacy Blog posts on treatment de-escalation

Question about COVID19? Send an email

Deadlines

NGS lab proposals for NCI-ComboMATCH due Sept. 30 

Latest News

ENDURANCE trial results: There was no improvement in progression-free survival by replacing bortezomib with carfilzomib in the current standard initial treatment of patients with newly diagnosed standard- or intermediate-risk myeloma. August 28, 2020, The Lancet 

In the latest NCI-MATCH news, April K.S. Salama, MD, and colleagues report that the combination of dabrafenib and trametinib elicited favorable response rates. This promising activity warrants more investigations in BRAF^V600-mutated tumors outside of currently approved indications. August 13, 2020, OncLive

Results of the EA5161 trial are “striking ASCO 2020 data” and significant for patients with extensive small-cell lung cancer because adding nivolumab improved progression-free and overall survival. August 5, 2020, OncLive

Black Scientists Still Face an Uphill Battle in Securing NIH Research Grants: an interview with Edith P. Mitchell, MD (Thomas Jefferson U). “What we have to do is work in all areas and that’s what we’re doing in the ECOG-ACRIN Cancer Research Group, where I am a member of the executive committee.” July 15, 2020, Philadelphia Magazine

Taofeek Owonikoko, MD, PhD, MSCR (Emory U) on the results of trial EA5161: “Could there be unique differences between anti-PD-L1 and anti-PD-1 drugs? Possibly, however, I don’t think we can claim that such unique differences are significant enough to impact the efficacy of each in small-cell lung cancer.” July 15, 2020, Physician’s Weekly

For untreated follicular lymphoma, study E2408 shows that neither bortezomib added to bendamustine/rituximab (BR) induction nor lenalidomide added to rituximab maintenance immediately post-BR induction is recommended, per Andrew M. Evans, MD (Rutgers Cancer Institute of New Jersy) and colleagues. July 10, 2020, Clinical Cancer Research

Surprising Results from the PALLAS Trial: a discussion with Kathy D. Miller, MD (Indiana U). “More than anything else, this trial reminds us of the absolute necessity of putting our ideas to the test and doing appropriately powered, appropriately controlled, and well-conducted randomized trials.” July 1, 2020, Medscape

Study Shows Better Option for Treatment of Inoperable Anal Cancer: an article featuring Cathy Eng, MD (Vanderbilt U), lead investigator for InterAAct (EA2133), the first international prospective, randomized trial for advanced anal cancer. June 24, 2020, Science Magazine

Looking for more (older) news coverage? Visit the News and Info section and the TMIST Press Center.

YouTube Highlights

View our YouTube channel for these and other videos:

• EA8143/PROSPER RCC Clinical Trial for Renal Cell Carcinoma
  
  
• Spring 2020 Virtual Town Hall on COVID-19 
   
• Strategies to Include Minority Women in the TMIST Breast Cancer Screening Trial

Acknowledgments

Welcome

Welcome to the ECOG-ACRIN Cancer Research Group website, the source of information about the cooperative group that was formed by the merger of the Eastern Cooperative Oncology Group (ECOG) and the American College of Radiology Imaging Network (ACRIN). We are excited to share news of our collaborative effort to design and conduct ground-breaking translational and clinical research.

The merger brought together the strengths and capabilities of two highly respected organizations. Since 1955, ECOG has performed practice-changing multicenter cancer clinical trials, working with more than 6000 physicians, nurses, pharmacists, statisticians, clinical research associates, and cancer research advocates from the United States and around the world. ACRIN, the premier imaging science program in the nation, complements ECOG’s research efforts with its expertise in early detection, imaging diagnosis, comparative-effectiveness research, and cost-effectiveness analysis. Now, as a single entity, we aim to achieve earlier cancer detection, more successful therapeutic intervention, higher rates of prevention, and better patient outcomes.

We look forward to sharing our research and partnering with you, as we reshape the future of patient care.

 

Robert L. Comis, MD
Group Co-Chair

Mitchell D. Schnall, MD, PhD
Group Co-Chair